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menopause-related symptoms
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and Stephen Cho Wing Sze1*
Abstract 
Background: Erxian decoction (EXD) is used to treat menopause‑related symptoms in Chinese medicine. This study 
aims to identify the bioactive compounds and potential actions of EXD by network pharmacological analysis.
Methods: Two databases, the Traditional Chinese Medicine Systems Pharmacology database and TCM Database@
Taiwan, were used to retrieve literature of phytochemicals of EXD. STITCH 4.0 and the Comparative Toxicogenomics 
Database were used to search for compound–protein and compound–gene interactions, respectively. DAVID Bioin‑
formatics Resources 6.7 and Cytoscape 3.01 with Jepetto plugin software were used to perform a network pharmaco‑
logical analysis of EXD.
Results: A total of 721 compounds were identified in EXD, of which 155 exhibited 2,656 compound–protein interac‑
tions with 1,963 associated proteins determined by STITCH4.0 database, and of which 210 had 14,893 compound–
gene interactions with 8,536 associated genes determined by Comparative Toxicogenomics Database. Sixty three 
compounds of EXD followed the Lipinski’s Rule with OB ≥30% and DL index ≥0.18, of which 20 related to 34 signifi‑
cant pathway‑ or 12 gene‑ associated with menopause.
Conclusions: Twenty compounds were identified by network pharmacology as potential effective ingredients of 
EXD for relieving menopause with acceptable oral bioavailability and druggability.
© 2015 Wang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
By the age of 35 years, the quality and quantity of ovar-
ian follicles would decline [1], and consequential hormo-
nal and symptomatic changes would lead to cessation of 
menses [2]. During menopause, the fluctuating levels of 
sex hormones, including luteinizing hormone, follicle-
stimulating hormone, estrogen, and progesterone [3], 
can cause osteoporosis and menopausal symptoms, such 
as hot flushes, depression, nocturnal sweating, uterine 
bleeding, vaginal dryness, insomnia, and loss of sexual 
function [4–6]. It is estimated that there will be about 1.2 
billion menopausal women worldwide by 2030 [7]. Men-
opause occurs between 44.6 and 52 years of age, varying 
among different races and countries [8]. In the United 
States, about 6,000 women reach menopause every day, 
which is more than 2 million per year [7]. The average age 
of menopause in the United Kingdom and United States 
is 52 and 51 years, respectively [9, 10]. In China, women 
around 50 years of age would experience natural meno-
pause and in the southeast of China reach menopause 
at an average age of 48.9 years [11, 12]; thus, 0.28 billion 
women will be over the age of 50  years by 2030 would 
have menopause [13].
Hormone replacement therapy (HRT) has been used 
for more than 60 years to relieve menopausal symptoms. 
However, there are many adverse effects associated with 
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HRT [14], e.g., increasing the risks of breast cancer, coro-
nary artery disease, endometrial cancer, venous throm-
boembolism and stroke [15].
Chinese medicines (CM) are also used in treating 
menopausal symptoms [16–21]. Some Chinese herbal 
formulas (CHFs) are indicative for treating gynecologi-
cal disorders including menopausal symptoms [16, 17]. 
However, few studies on the biological actions of the 
CHFs have been conducted [24–26]. As a typical exam-
ple for CHFs, Erxian decoction (EXD) is commonly used 
to treat menopause related symptoms [17, 22–34], con-
sisting of six herbs, Herba Epimedium Brevicornum (HE; 
Xian-ling-pi), Rhizoma Curculiginis Orchioides (RC; 
Xian-mao), Radix Morindae Officinalis (RMO; Ba-ji-
tian), Radix Angelicae Sinensis (RAS; Dang-gui), Cortex 
Phellodendri Chinensis (CPC; Huang-bo), and Rhizoma 
Anemarrhenae Asphodeloides (RA; Zhi-mu) [35].
During the past two decades, drug discovery has pur-
sued a dominant target, “one drug, one disease” para-
digm. However, many drugs exert therapeutic  effects 
via restoration of multiple disease-related targets 
rather than a  single one [36, 37]. Network pharmacol-
ogy, which is based on systems biology, polypharma-
cology and molecular network analysis, provides a 
possible strategy to elucidate the action mechanism of 
multi-ingredient medicine in a holistic view [38–40]. 
Molecular networks are constructed by interactions 
of  target-based proteins and genes for predicting their 
function and facilitating drug discovery, which provides 
pharmacological information in a holistic manner [40, 
41]. Enrichment analysis is an analytical method to 
assess functional associations between sets of genes or 
proteins of interest to us and a database of known gene 
or protein sets [42, 43]. It can identify the significant 
pathways and their enriched gene/protein sets, and elu-
cidate significant multiple pharmacological mechanisms 
[42, 44].
The complexity of numerous chemical constituents and 
biological actions has not been fully identified in EXD. 
This study aims to identify the bioactive compounds and 
actions of EXD by a network pharmacological analysis.
Methods
The constituent compounds of EXD were identified by 
two phytochemical databases, the Traditional Chinese 
Medicine Systems Pharmacology (TCMSP) database and 
TCM Database@Taiwan., as well as published EXD lit-
eratures [26–30, 35, 45, 46]. The druggability analysis of 
the identified compounds in EXD were performed and 
provided by Lipinski’s rule (LR) and TCMSP database 
in term of oral bioavailability (OB) and drug-likeness 
(DL) indices, respectively. OB is the degree to which a 
drug or other substance becomes available to the target 
tissue after oral administration. DL is to evaluate their 
potentials to be bioactive compounds compare with 
the well-developed drug. The significant pathways and 
gene-associated diseases for the identified compounds 
were determined by enrichment analysis (JEPETTO 
(US): http://apps.cytoscape.org/apps/jepetto) [43] of the 
compound-protein interaction and enrichment analysis 
(DAVID 6.7 (US): http://david.abcc.ncifcrf.gov/home.jsp) 
[47] of the compound–gene interactions, respectively. 
The workflow of the network pharmacology study of 
EXD was summarized in Figure 1.
Identification of potential bioactive constituents in EXD
All phytochemicals from the six constituent herbs of 
EXD were identified by the TCM Database@Taiwan 
(http://tcm.cmu.edu.tw/), TCMSP database (http://
sm.nwsuaf.edu.cn/lsp/tcmsp.php), and previous EXD lit-
eratures [26–30, 35, 45, 46].
Druggability analysis by LR, OB and DL properties
Lipinski’s rule (LR) [48] was used to identify druggable 
compounds according to the following criteria: molecu-
lar weight (MW) of not more than 500 Da (MW ≤500), 
chemical composition with no more than five hydro-
gen bond donors (H-bond donors ≤5), no more than 
10 hydrogen bond acceptors (H-bond acceptors ≤10), 
and octanol–water partition coefficient, LogP, no >5 
(LogP ≤ 5). A compound that does not satisfy at least two 
of the above conditions is less likely to be an orally active 
drug [49].
The phytochemical information of the compounds 
with their OB and DL properties were explored using the 
TCMSP database, which embed OBioavail 1.1 software 
for OB [50] and Tanimoto similarity software for DL [51]. 
The DL calculations in TCMSP database were based on 
the following formula [51]:
where A is related to the molecular property of the target 
compound and B refers to the average molecular proper-
ties of all drugs from the Drugbank database (http://www.
drugbank.ca/). A more detailed calculation of the DL 
index can be found in Tao et al. [51] and Wang et al. [52]. 
The thresholds used were OB ≥30% and DL index ≥0.18, 
as recommended by the TCMSP database. The thresholds 
were selected to efficiently identify bioactive compounds 
from the large pool of chemical compounds based on the 
following criteria: (1) the model obtained could be rea-
sonably explained by previous pharmacological data and 
(2) the compound met the recommended mean DL index 
of 0.18 (the mean of DL index of 6,511 molecules from 
Drugbank database (2011) is 0.18) [51, 52].
F(A,B) = A×
B
A2 + B2 − A× B
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Identification of associated proteins and genes
The integrative efficacy of the identified constituents in 
EXD was determined by analyzing the chemical–pro-
tein and chemical–gene interactions obtained from the 
Search Tool for Interactions of Chemicals and Proteins 
(STITCH) database and Comparative Toxicogenomics 
Database (CTD), respectively. The STITCH 4.0 data-
base (http://stitch.embl.de/) can be used to study poten-
tial interactions between 300,000 phytochemicals and 
2.6 million proteins curated from 1,133 organisms [53]. 
In this database, the approximate probability of a pre-
dicted association for a chemical–protein interaction is 
determined by the confidence score, with a higher score 
indicating a stronger interaction (low confidence score 
~0.2; medium confidence score ~0.5; high confidence 
score ~0.75; highest confidence score ~0.95, provided by 
STITCH 4.0 database). The CTD (http://ctd.mdibl.org/) 
is a publicly available research resource that includes 
more than 116,000 interactions between 9,300 chemi-
cals and 13,300 genes [54]. Both databases were searched 
independently by two researchers to minimize any bias.
In order to identify the associated significant pathways, 
proteins with a chemical–protein interaction confidence 
score ≥0.5 were selected for the enrichment analy-
sis by JEPETTO with the KEGG database, a Java-based 
Cytoscape 3.01 plugin [43]. For studying the gene-associ-
ated diseases, the genes were firstly ranked by frequency 
of occurrence of the chemical–gene interactions, and 
then the genes with gene frequency ≥1.67 were chosen 
for the enrichment analysis by Visualization and Inte-
grated Discovery (DAVID) Bioinformatics Resources 6.7 
(http://david.abcc.ncifcrf.gov/).
Results
Compounds in EXD
Eight hundred and ninety-five phytochemicals were 
collected from the six herbs in EXD. From the TCM 
Database@Taiwan, 203 compounds were identified, com-
prising 29 in HE, 44 in RC, 38 in RMO, 56 in RAS, seven 
in CPC, and 29 in RA. From the TCMSP database, 646 
compounds were identified, comprising 130 in HE, 78 
in RC, 174 in RMO, 125 in RAS, 58 in CPC, and 81 in 
RA. 46 phytochemicals from previous studies in the lit-
erature [26–30, 35, 45, 46], comprising 15 in HE, one in 
RC, five in ROM, five in RAS, 14 in CPC, 5 in RA, and 
one in EXD (specific herbs unknown). Finally, a total of 
721 phytochemicals were identified in EXD after remov-
ing overlapping/duplicate compounds from the databases 
and the literature (Additional file 1).
Identifying druggable compounds by LR, OB, and DL 
predictions
Of the 150 compounds from HE, 75 (50%) compounds 
were identified based on LR, 23 (15.3%) had OB ≥30% 
TCM Database@Taiwan 
(http://tcm.cmu.edu.tw/) 
203 compounds 
TCMSP database 
(http://lsp.nwsuaf.edu.cn/tcmsp.php) 
646 compounds 
Literature of EXD by 
manual search 
46 compounds 
Compound-protein interaction 
information (STITCH 4.0) 
155 compounds 
1,963 associated proteins 
2,656 compound–protein interactions 
Compound-gene interaction 
information (CTD) 
210 compounds 
8,536 associated genes 
14,893 compound–gene interactions 
Druggability  
Analysis  
Lipinski’s Rule ,  
OB≥30% & DL≥0.18 
(TCMSP) 
63 calculated druggable 
compounds 
12 gene-associated 
diseases related to 
menopause 
(P ≤ 0.01)
34 significant 
pathways involved 
(XD-Score ≥ 0.67)  
Enrichment analysis 
(JEPETTO)  
1,824 associated proteins 
(Confidence score ≥ 0.5) 
Enrichment analysis 
(DAVID 6.7)  
2,183 associated genes 
(Gene frequency ≥ 1.74) 
721 Phytochemical identification  
(After removing overlapping/duplicate compounds) 
Network Pharmacology of 721 identified compounds 
20 EXD bioactive 
compounds related to 34 
significant pathway- or 12 
gene- associated with 
menopause (Table 3) 
Figure 1 The workflow of the network pharmacological study of EXD.
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and DL index ≥0.18, and only 17 (11.3%) satisfied all cri-
teria. Of the 104 compounds from RC, 29 (27.9%) passed 
LR, seven (6.7%) had OB ≥30% and DL index ≥0.18, and 
only four (3.8%) satisfied all criteria. Of the 189 com-
pounds from RMO, 125 (66.1%) passed LR, 20 (10.6%) 
had OB ≥30% and DL index ≥0.18, and only 12 (6.3%) 
satisfied all criteria. Of the 173 compounds from RAS, 
131 (75.7%) passed LR, five (2.9%) had OB ≥30% and DL 
index ≥0.18, and only three (1.7%) satisfied all criteria. Of 
the 63 compounds from CPC, 43 (68.3%) passed LR, 28 
(44.4%) had OB ≥30% and DL index ≥0.18, and only 19 
(30.2%) satisfied all criteria. Of the 81 compounds from 
RA, 45 (55.6%) passed LR, 15 (18.5%) had OB ≥30% and 
DL index ≥0.18, and only 11 (13.6%) satisfied all criteria 
(Table  1). The physicochemical properties of anemar-
saponin BII from EXD reported in the literature (specific 
herbs unknown) did not pass LR. Overall, 66 compounds 
passed LR and had OB ≥30% and DL index ≥0.18. A 
total of 63 compounds were obtained after removing the 
duplicate compounds (Table 2).
Table 1 Compounds in EXD satisfying LR, OB ≥30% and DL ≥0.18
LR Lipinski’s rule, OB oral bioavailability, DL drug-likeness index, HE Herba Epimedium Brevicornum, RC Rhizoma Curculiginis Orchioides, RMO Radix Morindae Officinalis, 
RAS Radix Angelicae Sinensis, CPC Cortex Phellodendri Chinensis, RA Rhizoma Anemarrhenae asphodeloides.
Herbs
HE RC RMO RAS CPC RA
Number of compounds 150 104 189 173 63 81
Compounds (percentage) passing LR 75 (50.0%) 29 (27.9%) 125 (66.1%) 131 (75.7%) 43 (68.3%) 45 (55.6%)
Compounds (percentage) with OB ≥30% and DL ≥0.18 23 (15.3%) 7 (6.7%) 20 (10.6%) 5 (2.9%) 28 (44.4%) 15 (18.5%)
Compounds (percentage) satisfying LR, OB ≥30% and DL ≥0.18 17 (11.3%) 4 (3.8%) 12 (6.3%) 3 (1.7%) 19 (30.2%) 11 (13.6%)
Table 2 The 63 bioactive compounds from HE, RC, RMO, RAS, CPC, and RA herbs and their corresponding molecular prop-
erties, OB and DL (20 of 63 bioactive compounds related to 34 significant pathway- or 12 gene- associated with meno-
pause)
Phytochemical MW AlogP Hdon Hacc OB (%) DL Herb
1. DFV((2S)‑7‑hydroxy‑2‑(4‑hydroxyphenyl)chroman‑4‑one)b 256.27 2.57 2 4 32.76 0.18 HE
2. Delta7‑dehydrosophoramine 242.35 1.09 0 3 54.45 0.25 CPC
3. Alizarin‑2‑methylether 254.25 2.53 1 4 32.81 0.21 RMO
4. 1‑Hydroxy‑3‑methoxy‑9,10‑anthraquinone 254.25 2.53 1 4 104.33 0.21 RMO
5. 1‑Hydroxy‑6‑hydroxymethylanthracenequinone 254.25 1.94 2 4 81.77 0.21 RMO
6. Skimmianin (4,7,8‑trimethoxyfuro[2,3‑b]quinoline) 259.28 2.33 0 5 40.14 0.20 CPC
7. Magnograndiolide ((3aS,6R,6aR,9R,9aS,9bS)‑6,9‑dihydroxy‑6,9‑dimethyl‑3‑methyl‑
idene‑3a,4,5,6a,7,8,9a,9b‑octahydroazuleno[5,4‑d]furan‑2‑one)
266.37 1.18 2 4 63.71 0.19 HE/CPC
8. Coumaroyltyramine (cis‑N‑p‑Coumaroyltyramine) 283.35 2.88 3 4 112.9 0.20 RA
9. Kaempferol(3,5,7‑trihydroxy‑2‑(4‑hydroxyphenyl)chromen‑4‑one)b 286.25 1.77 4 6 41.88 0.24 HE/RA
10. Luteolin(2‑(3,4‑dihydroxyphenyl)‑5,7‑dihydroxychromen‑4‑one)b 286.25 2.07 4 6 36.16 0.25 HE
11. Rutaecarpine(Indolo(2′,3′:3,4)pyrido(2,1‑b)quinazolin‑5(7H)‑one, 8,13‑dihydro‑(9CI))b 287.34 3.36 1 3 40.30 0.60 CPC
12. 8‑(3‑methylbut‑2‑enyl)‑2‑phenyl‑chromone 290.38 4.99 0 2 48.54 0.25 HE
13. Dehydrotanshinone II A (1,6,6‑trimethyl‑7H‑naphtho[5,6‑g] [1] benzoxole‑10,11‑dione) 292.35 4.22 0 3 43.76 0.40 CPC
14. Chryseriol(5,7‑dihydroxy‑2‑(4‑hydroxy‑3‑methoxyphenyl)chromen‑4‑one)b 300.28 2.32 3 6 35.85 0.27 HE
15. Phellopterin(4‑methoxy‑9‑(3‑methylbut‑2‑enoxy)furo[3,2‑g]chromen‑7‑one)b 300.33 3.64 0 5 40.19 0.28 CPC
16. Cnidilin(9‑methoxy‑4‑(3‑methylbut‑2‑enoxy)furo[3,2‑g]chromen‑7‑one)b 300.33 3.64 0 5 32.69 0.28 RAS
17. Quercetin(2‑(3,4‑dihydroxyphenyl)‑3,5,7‑trihydroxychromen‑4‑one)b 302.25 1.50 5 7 46.43 0.28 HE
18. (Z)‑3‑(4‑hydroxy‑3‑methoxy‑phenyl)‑N‑[2‑(4‑hydroxyphenyl)ethyl]acrylamide 313.38 2.86 3 5 118.35 0.26 RA
19. 1,6‑dihydroxy‑5‑methoxy‑2‑(methoxymethyl)‑9,10‑anthraquinone 314.31 2.06 2 6 104.54 0.34 RMO
20. Hippeastrine(Lycorenan‑7‑one, 5‑hydroxy‑1‑methyl‑9,10‑(methylenebis(oxy))‑, (5alpha)‑) 315.35 1.17 1 6 51.65 0.62 RA
21. Coptisine(6,7‑dihydro‑bis(1,3)benzodioxolo (5,6‑a:4′,5′‑g)quinolizinium) 320.34 3.25 0 4 30.67 0.86 CPC
22. 1,2‑bis(4‑hydroxy‑3‑methoxyphenyl)propan‑1,3‑diol 320.37 1.69 4 6 52.31 0.22 HE
23. 2‑Hydroxy‑1,5‑dimethoxy‑6‑(methoxymethyl)‑9,10‑anthraquinone 328.34 2.31 1 6 95.85 0.37 RMO
24. 2‑Hydroxy‑1,8‑dimethoxy‑7‑methoxymethylanthracenequinone 328.34 2.31 1 6 112.30 0.37 RMO
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Table 2 continued
Phytochemical MW AlogP Hdon Hacc OB (%) DL Herb
25. Americanin Aa 328.34 2.30 3 6 46.71 0.35 RMO
26. C‑Homoerythrinan, 1,6‑didehydro‑3,15,16‑trimethoxy‑, (3.beta.) 329.48 2.89 0 4 39.14 0.49 HE
27. 1,5,7‑Trihydroxy‑6‑methoxy‑2‑methoxymethylanthracenequinone 330.31 1.79 3 7 80.42 0.38 RMO
28. (2R,3S)‑(+)‑3′,5‑Dihydroxy‑4,7‑dimethoxydihydroflavonol 332.33 1.99 3 7 77.24 0.33 RMO
29. 2‑Hydroxyethyl 5‑hydroxy‑2‑(2‑hydroxybenzoyl)‑4‑(hydroxymethyl)benzoate 332.33 1.41 4 7 62.32 0.26 RMO
30. Chelerythrinea,b 332.37 4.29 0 4 34.18 0.78 CPC
31. Woreninea 334.37 3.73 0 4 45.83 0.87 CPC
32. Yinyanghuo C(2‑(2,2‑dimethylchromen‑6‑yl)‑5,7‑dihydroxychromen‑4‑one) 336.36 3.39 2 5 45.67 0.50 HE
33. Berberinea,b 336.39 3.45 0 4 36.86 0.78 CPC
34. Isocorypalmine ((13aS)‑5,8,13,13a‑tetrahydro‑3,9,10‑trimethoxy‑6H‑Dibenzo[a,g]quinolizin‑
2‑ol)
341.44 3.35 1 5 35.77 0.59 CPC
35. Yinyanghuo E (5,7‑dihydroxy‑2‑(8‑hydroxy‑2,2‑dimethylchromen‑6‑yl)chromen‑4‑one) 352.36 3.12 3 6 51.63 0.55 HE
36. Palmatine(Palmatine chloride is another name in TCMSP database)b 352.44 3.65 0 4 64.6 0.65 CPC
37. Fumarine(7‑methyl‑6,8,9,16‑tetrahydrobis[1, 3]benzodioxolo[4,5‑c:5′,6′‑g]azecin‑15(7H)‑
one)b
353.40 2.95 0 6 59.26 0.83 CPC
38. Cavidine(9‑dimethoxy‑6‑methyl‑6,6a,11,14‑tetrahydro‑8,12H‑
benzo(a)‑1,3‑benzodioxolo(4,5‑g)quinolizine)
353.45 3.72 0 5 35.64 0.81 CPC
39. 8‑Isopentenyl‑kaempferolb 354.38 3.63 4 6 38.04 0.39 HE
40. Anhydroicaritin(3,5,7‑trihydroxy‑2‑(4‑methoxyphenyl)‑8‑(3‑methylbut‑2‑enyl)chromen‑4‑
one)b
368.41 3.88 3 6 45.41 0.44 HE/RA
41. Suchilactonea 368.41 3.73 0 6 57.52 0.56 RAS
42. 6‑Hydroxy‑11,12‑dimethoxy‑2,2‑dimethyl‑1,8‑dioxo‑2,3,4,8‑tetrahydro‑43.1H‑
isochromeno[3,4‑h]isoquinolin‑2‑ium
370.41 2.75 1 6 60.64 0.66 HE
43. Ohioensin‑Aa 372.39 3.57 3 5 38.13 0.76 RMO
44. Phellavin_qta 374.42 2.51 5 7 35.86 0.44 CPC
45. Olivila 376.44 1.68 4 7 62.23 0.41 HE
46. Jatrorrhizinea,b 380.5 4.44 1 4 30.44 0.75 CPC
47. Stigmasterol((3S,8S,9S,10R,13R,14S,17R)‑17‑[(2R,5S)‑5‑ethyl‑6‑methylhept‑3‑en‑2‑yl]‑10,13‑
dimethyl‑2,3,4,7,8,9,11,12,14,15,16,17‑dodecahydro‑1H‑cyclopenta[a]phenanthren‑3‑ol)b
412.77 7.64 1 1 43.83 0.76 RC
48. Diosgenin((3β,25R)‑spirost‑5‑en‑3‑ol)b 414.69 4.63 1 3 80.88 0.81 RA
49. ZINC03982454((3R,8S,9S,10R,13R,14R,17R)‑17‑[(2R,5S)‑5‑ethyl‑6‑methylheptan‑2‑yl]‑10,13‑
dimethyl‑2,3,4,7,8,9,11,12,14,15,16,17‑dodecahydro‑1H‑cyclopenta[a]phenanthren‑3‑ol)
414.79 8.08 1 1 36.91 0.76 RC
50. Beta‑sitosterol(17‑(5‑Ethyl‑6‑methylheptan‑2‑yl)‑10,13‑dimethyl‑ 
2,3,4,7,8,9,11,12,14,15,16,17‑dodecahydro‑1H‑cyclopenta[a]phenanthren‑3‑ol)b
414.79 8.08 1 1 36.91 0.75 RC
51. Timosaponin B III_qta 416.71 4.77 2 3 35.26 0.87 RA
52. Anemarsaponin C_qta 416.71 4.97 2 3 35.50 0.87 RA
53. Phyllanthin(4‑[(2S,3S)‑3‑[(3,4‑dimethoxyphenyl)methyl]‑4‑methoxy‑2‑(methoxymethyl)
butyl]‑1,2‑dimethoxybenzene)
418.58 4.11 0 6 33.31 0.42 RAS
54. Yinyanghuo Aa 420.49 4.20 3 6 56.96 0.77 HE
55. Cycloartenol (9beta,19‑Cyclo‑24‑lanosten‑3beta‑ol)b 426.80 7.55 1 1 38.69 0.78 RC
56. Anemarsaponin F_qta 432.71 3.92 2 4 60.06 0.79 RA
57. Asperglaucide(aurantiamide acetate) 444.57 4.02 2 6 58.02 0.52 RA
58. Anemarsaponin E_qta 448.76 4.53 2 4 30.67 0.86 RA
59. Obacunonea,b 454.56 2.68 0 7 43.29 0.77 CPC
60. Icariside A7((2R,3S,4S,5R,6S)‑2‑(hydroxymethyl)‑6‑(7‑hydroxy‑3,4,6‑trimethoxyphenan‑
thren‑2‑yl)oxyoxane‑3,4,5‑triol0
462.49 1.16 5 10 31.91 0.86 HE
61. Hispidonea 472.78 4.46 2 4 36.18 0.83 CPC
62. Kihadanin Aa 486.56 1.76 1 9 31.60 0.70 CPC
63. Isoprincepina 494.53 2.52 5 9 49.12 0.77 RMO
HE herba Epimedium Brevicornum, RC Rhizoma Curculiginis Orchioides, RMO Radix Morindae Officinalis, RAS Radix Angelicae Sinensis, CPC Cortex Phellodendri Chinensis, 
RA Rhizoma Anemarrhenae Asphodeloides.
a IUPAC name were not provided in database.
b 20 EXD bioactive compounds related to 34 significant pathway- or 12 gene- associated with menopause.
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Revealing the significant pathways and gene‑associated 
diseases
Overall, 155 of the 721 compounds from EXD were found 
to have 2,656 chemical–protein interactions. After remov-
ing the overlapping/duplicate information, 1,963 associ-
ated proteins were obtained (Additional file  2). 1,824 of 
1,963 proteins with a confidence score exceeding 0.5 were 
obtained. After enrichment analysis of 1,824 associated 
proteins, XD-scores and q values of pathways have been 
obtained. The XD-score is relative to the average distance 
to all pathways and represents a deviation from the aver-
age distance [43]. A larger positive XD-score indicates a 
stronger association between the inputted associated 
proteins and molecular interaction network of pathways. 
The q value determines the significance of the overlap 
(Fisher’s exact test) between the input information and 
the pathways. The enrichment algorithm analysis (graph-
based statistic) of XD-score and q-value revealed that the 
threshold value of XD-score in this study was 0.67, there-
fore there are 34 pathways significantly associated with 
input set of proteins (Table 3).
In total, 210 of the 721 compounds from EXD were 
found to have 14,893 compound–gene interactions with 
8,536 associated genes in the CTD (Additional file 3). Sub-
sequently, the 8,536 genes were ranked according to their 
frequency of occurrence. The number of genes fell abruptly 
when the frequency of occurrence was small (gene fre-
quency ≤8; Figure 2). Subsequently, the number of genes 
became stabilized for gene frequencies between 10 and 
19. However, the number of genes with gene frequencies 
≥20 was quite small. Genes with gene frequencies below 
the average of 1.74 were removed to reduce the number 
of redundant genes. After that, the remaining 2,183 genes 
were used to conduct the gene enrichment analysis by the 
DAVID platform. The “GENETIC_ASSOCIATION_DB_
DISEASE_CLASS” was selected as the annotation cat-
egory to search for the significant diseases associated with 
the input genes, which was statistically verified by Fisher’s 
exact test using the DAVID platform [47]. P ≤  0.01 indi-
cated significant association or enrichment with the related 
items. After removing nonspecific diseases, 12 classes of 
diseases were found to be highly associated with the input 
genes (Tables 4 and 5). Most of these diseases were related 
to menopause, such as aging, reproduction, cancer, cardio-
vascular diseases, and neurological diseases [55–58].
Identifying twenty bioactive compounds related 
to menopause with following the druggability prediction
Eighteen of the 155 compounds that have 2,656 chemi-
cal–protein interaction, followed the Lipinski’s Rule with 
OB ≥30% and DL index ≥0.18. Thirteen of the 210 com-
pounds that have compound–gene interactions interaction, 
followed the Lipinski’s Rule with OB ≥30% and DL index 
≥0.18. Finally, 11 compounds has been identified related to 
both chemical–gene and chemical–protein interaction and 
followed the druglikeness prediction. Moreover, 20 com-
pounds related to 34 significant pathway- or 12 gene- asso-
ciated with menopause have been identified (Table 3).
Discussion
The actions of bioactive compounds in EXD were inves-
tigated by combining a drug prediction method with an 
enrichment analysis using information from bioinformatics 
Table 3 The 34 significant pathways found by  JEPETTO 
(Cytoscape plugin) with KEGG database
Pathway XD‑score q value Overlap/size
Linoleic acid metabolism 3.148 0.000 10/11
Citrate cycle (TCA cycle) 3.057 0.000 21/26
Propanoate metabolism 1.899 0.000 11/19
Arachidonic acid metabolism 1.865 0.000 17/26
PPAR signaling pathway 1.794 0.000 22/39
Tyrosine metabolism 1.475 0.001 9/17
Retinol metabolism 1.474 0.009 6/12
Bladder cancer 1.463 0.000 17/38
Ether lipid metabolism 1.370 0.002 8/16
Metabolism of xenobiotics by 
cytochrome P450
1.313 0.001 10/20
Adipocytokine signaling pathway 1.248 0.000 24/57
Drug metabolism: cytochrome 
P450
1.240 0.003 8/17
Fatty acid metabolism 1.096 0.000 12/26
Pyruvate metabolism 1.096 0.000 12/26
One carbon pool by folate 1.057 0.018 5/10
Glyoxylate and dicarboxylate 
metabolism
1.057 0.018 5/10
Fc epsilon RI signaling pathway 1.040 0.000 23/65
Pancreatic cancer 1.013 0.000 25/70
Steroid hormone biosynthesis 0.990 0.027 6/15
GnRH signaling pathway 0.969 0.000 32/83
Beta‑Alanine metabolism 0.924 0.007 7/15
Prostate cancer 0.913 0.000 32/84
Tryptophan metabolism 0.903 0.000 12/26
Long‑term depression 0.893 0.000 23/57
Toll‑like receptor signaling pathway 0.883 0.000 32/90
NOD‑like receptor signaling 
pathway
0.879 0.000 21/59
Biosynthesis of unsaturated fatty 
acids
0.875 0.027 5/11
Riboflavin metabolism 0.875 0.027 5/11
VEGF signaling pathway 0.872 0.000 24/62
Glycerophospholipid metabolism 0.829 0.002 13/35
Type II diabetes mellitus 0.814 0.010 13/43
Chagas disease 0.804 0.000 36/99
Selenoamino acid metabolism 0.763 0.049 6/17
Renal cell carcinoma 0.708 0.000 24/68
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databases at the gene and protein levels. For example, 
candidate compounds such as berberine, palmatine, and 
jatrorrhizine, which we identified using our drug prediction 
method, have been shown to exhibit extensive pharma-
cological activities [59, 60]. From the enrichment analysis 
based on the available information for compound–protein 
and compound–gene interactions of EXD, we identified 
the most significantly related pathways and gene-associ-
ated disease, including pathways related to endocrine [35], 
VEGF [61], lipid metabolism [62] and anti-inflammatory 
[34]. Their pharmacological association with EXD were in 
line with previous publications [34, 35, 61, 62].
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Figure 2 Gene frequency of the associated genes of 210 compounds.
Table 4 Chemical–protein interactions and related significant signaling pathways
Herb Compound Protein Pathway
HE Emodin (1,3,8‑trihydroxy‑6‑methylanthracene‑9,10‑dione) HSD11B1 Steroid hormone biosynthesis
RMO Alcool methylique SULT2B1 Steroid hormone biosynthesis
CPC Phenanthrene(TCMSP don’t record IUPAC name) CYP1A1 Steroid hormone biosynthesis
RMO Caffeic acid ((Z)‑3‑(3,4‑dihydroxyphenyl)prop‑2‑enoic acid) COMT Steroid hormone biosynthesis
HE Quercetin(2‑(3,4‑dihydroxyphenyl)‑3,5,7‑trihydroxychromen‑4‑one) CYP19A1 Steroid hormone biosynthesis
HE Quercetin‑3‑O‑glucoside CYP1B1 Steroid hormone biosynthesis
HE Apigenin(5,7‑dihydroxy‑2‑(4‑hydroxyphenyl)chromen‑4‑one) PTK2 VEGF signaling pathway
RMO Hemo‑sol((4R)‑1‑methyl‑4‑prop‑1‑en‑2‑ylcyclohexene) HRAS VEGF signaling pathway
HE/RA Kaempferol(3,5,7‑trihydroxy‑2‑(4‑hydroxyphenyl)chromen‑4‑one) MAPK1/AKT1/SRC VEGF signaling pathway
RMO Esculetin(6,7‑dihydroxychromen‑2‑one) MAPK3 VEGF signaling pathway
RMO Citric acid(2‑hydroxypropane‑1,2,3‑tricarboxylic acid) KRAS VEGF signaling pathway
HE Oleanolic acid((3‑beta)‑3‑Hydroxyolean‑12‑en‑28‑oic acid) MAPK14 VEGF signaling pathway
RAS Adenine(7H‑purin‑6‑amine) PTGS2 VEGF signaling pathway
HE Emodin(1,8‑dihydroxy‑3‑(hydroxymethyl)anthracene‑9,10‑dione) VEGFA VEGF signaling pathway
HE Luteolin(2‑(3,4‑dihydroxyphenyl)‑5,7‑dihydroxychromen‑4‑one) PIK3CB VEGF signaling pathway
RA 3,5,7‑Trihydroxy‑4′‑methoxyl‑8‑prenylflavone‑3‑O‑rhamnopyranoside CASP9 VEGF signaling pathway
RC/RMO Myristic acid PPP3CB/PPP3CA VEGF signaling pathway
RC/RMO/RAS Palmitic acid NOS3 VEGF signaling pathway
RAS Lecithin PLA2G4A VEGF signaling pathway
HE/RMO Lauric acid PIK3CA VEGF signaling pathway
RA Chinoinin(1,3,6,7‑tetrahydroxy‑2‑[(2S,3R,4R,5S,6R)‑3,4,5‑trihydroxy‑6‑(hydroxymethyl)
oxan‑2‑yl]xanthen‑9‑one)
PLA2G2A VEGF signaling pathway
RAS 4‑Methoxybenzoic acid PLA2G1B VEGF signaling pathway
RMO Nonanoic acid NFAT5/NFATC3 VEGF signaling pathway
RMO (9Z,12Z)‑octadeca‑9,12‑dienoic acid PLA2G10/PLA2G5 VEGF signaling pathway
RC/RMO Myristic acid PPP3CC VEGF signaling pathway
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Table 5 The 12 disease classes highly associated with input genes
Disease class Number of input genes involved in the disease Input genes/total genes involved in the disease (%) P value
Cancer 384 14.5 9.4E−28
Cardiovascular 342 12.9 2.8E−25
Aging 79 3.0 8.7E−17
Reproduction 133 5.0 1.3E−11
Renal 100 3.8 2.5E−10
Neurological 247 9.3 1.9E−7
Infection 142 5.4 2.0E−7
Psychological 238 9.0 2.9E−7
Immune 316 11.9 1.4E−5
Hematological 70 2.6 1.4E−4
Vision 85 3.2 4.4E−4
Developmental 105 4.0 6.4E−3
Figure 3 Chemical–protein interactions related to steroid hormone biosynthesis pathways. The grey color represents genes in the target set, green 
relates to the steroid hormone biosynthesis pathway, blue (labeled) is the overlap between the related pathway and the input protein set.
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Several pathways involved the endocrine have also been 
identified, such as steroid hormone biosynthesis, GnRH 
signaling pathway, and adipocytokine signaling pathway, 
covering the previous finding of our group to promote 
estradiol biosynthesis in animal study [35]. For the steroid 
hormone biosynthesis signaling pathways, the EXD com-
pound, quercetin, promoted the expression of aromatase 
(CYP19A1), which is the enzyme for estrogen biosynthe-
sis [63]. This compound also met the druggability criteria. 
Other important overlapping proteins were HSD11B1, 
SULT2B1, CYP1A1, COMT, and CYP1B1 (Figure 3).
For the VEGF signaling pathways, VEGFA protein was 
involved in the antiangiogenic ability of EXD from our 
previous study [61]. The anti-cancer effect of EXD com-
pound interact with VEGFA, emodin, has been reported 
[64]. Other interacting proteins of significance were 
PTK2, HRAS, MAPK1, AKT1, SRC, MAPK3, KRAS, 
MAPK14, PTGS2, PIK3CB, CASP9, PPP3CB, PPP3CA, 
NOS3, PLA2G4A, PIK3CA, PLA2G2A, PLA2G1B, 
NFAT5, NFATC3, PLA2G10, PLA2G5, and PPP3CC (Fig-
ure 4). The steroid hormone biosynthesis and VEGF sign-
aling pathways were selected for further analysis in the 
present study (Table 5).
For the lipid metabolism, EXD associated-pathways 
related to linoleic acid metabolism, fatty acid metabo-
lism, unsaturated fatty acid biosynthesis, glycerophos-
pholipid metabolism, arachidonic acid metabolism, and 
PPAR were identified [65–69]. Besides, our previous 
study found that EXD could improve the lipid profile in 
cardiovascular disease [62].
While a previous study showed EXD to have anti-
inflammatory activity [34], the present study suggested 
Figure 4 Chemical–protein interactions related to the VEGF signaling pathway. The grey color represents genes in the target set, green relates to 
the VEGF pathway, blue (labeled) is the overlap between the related pathway and the input protein set. The orange is the expansion of their path‑
ways.
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the pathways to include the Toll-like receptor signaling 
pathway, NOD-like receptor signaling pathway, and Fc 
epsilon RI signaling pathway [70–72]. This findings were 
consistent with previous studies on EXD antimetastatic 
activity in a human ovarian cancer model [73] and its 
antiangiogenic properties [61].
Compound–compound interactions were not consid-
ered in this study because the available databases could 
only provide limited information for the six individual 
herbs. The information of the databases did not cover 
the new compounds synthesized by chemical reactions 
during the decoction of EXD’s ingredients, which will 
be confirmed by liquid chromatograph couple with mass 
spectrometry in further study. The ranking of the com-
pound–gene and compound–protein interaction infor-
mation was based on published evidence, but qualify of 
this evidence still needs extensive assessment. This study 
exemplified how to screen and identify bioactive com-
pounds in CHFs.
Conclusions
Twenty compounds were identified by network phar-
macology as potential effective ingredients of EXD  for 
menopause with acceptable oral bioavailability and 
druggability.
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